Bortezomib: a new therapeutic option for POEMS syndrome

Eur J Haematol. 2010 Feb 1;84(2):175-7. doi: 10.1111/j.1600-0609.2009.01341.x. Epub 2009 Sep 3.

Abstract

Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.

Methods: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.

Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.

Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Glycoproteins / blood
  • Humans
  • Male
  • POEMS Syndrome / blood
  • POEMS Syndrome / drug therapy*
  • Pyrazines / administration & dosage*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Glycoproteins
  • Pyrazines
  • protein M (glycoprotein)
  • Bortezomib